The ZNF737-CXCL10 axis drives immune exclusion and resistance to anti-PD-1 therapy in bladder cancer.

Decoding metabolic reprogramming heterogeneity across bladder cancer stages using single-cell and spatial multi-omics approaches.

Oncogenic epigenetic factor EP300 is a potential therapeutic target for bladder carcinoma.

Incidental prostate cancer is frequently identified in men undergoing radical cystoprostatectomy for urothelial carcinoma of the bladder. While usually clinically insignificant, its long natural history raises questions about long-term impact as systemic therapies prolong bladder cancer survival. The aim of this study is to describe the natural history, recurrence patterns, and survival outcomes of prostate cancer detected incidentally following radical cystoprostatectomy in a prospective cohort, and to provide a follow-up protocol for these patients. A retrospective cohort study with prospective follow-up of consecutive men undergoing radical cystoprostatectomy with urinary diversion for urothelial carcinoma at a tertiary referral center (1999-2020) was conducted. Follow-up included serial prostate-specific antigen (PSA) testing, imaging, and cause-specific survival. Associations with recurrence and survival were assessed using Cox regression. Incidental prostate cancer was diagnosed in 384 of 940 men (41%). Prostate cancer recurrence was reported in 23 men (6%) at a median of 25mo, most often in bone and lymph nodes. Seven patients died of prostate cancer at a median of 72mo after surgery. Risk factors for recurrence included higher International Society of Urological Pathology grade (hazard ratio [HR] 2.9, 95% confidence interval [CI] 2.2-3.9; p<0.001), locally advanced stage (HR 6.8, 95% CI 4.1-11.2; p<0.001), preoperative PSA (HR 2.3, 95% CI 1.4-3.8; p=0.002), and nodal metastasis (HR 29.3, 95% CI 10.8-79.3; p<0.001), although HR effect estimates were exploratory and based on a limited number of events. Overall survival was determined by bladder cancer stage, comorbidity, and age; prostate cancer features were prognostic only beyond 3yr. Incidental prostate cancer after radical cystoprostatectomy is usually organ confined and of low grade, with a low short-term risk. In long-term survivors with adverse pathological features, incidental prostate cancer represents a clinically non-negligible contributor to cause-specific mortality, despite a low absolute risk at the population level. Selective risk-adapted PSA surveillance should be considered in patients with higher-risk pathology and favorable bladder cancer outcomes following a protocol. We studied men with prostate cancer diagnosed incidentally during bladder cancer surgery. While most cases of prostate cancer were at a low risk and rarely caused early problems, some patients with higher-risk prostate cancer developed metastases or died from the disease later. Careful follow-up for prostate cancer may benefit selected long-term bladder cancer survivors.

Lactylation enhances YTHDF3 stability to promote cisplatin resistance via m6A-dependent KDM6B decay in bladder cancer.

HALP score as an independent prognostic biomarker for recurrence and progression in non-muscle-invasive bladder cancer: A retrospective cohort study.

LncRNA NPSR1-AS1 affects the malignant biological behavior of bladder cancer through miR-199a-3p and the clinical value of urine-derived lncRNA NPSR1-AS1.

Association of social isolation and loneliness with cancer prognosis: an analysis of the UK Biobank.

Efficacy and safety of tislelizumab plus intravesical chemotherapy in recurrent high-risk non-muscle-invasive bladder cancer: A retrospective single-center real-world study.

The immunosuppressive tumor microenvironment and poor drug targeting remain major obstacles in bladder cancer (BC) therapy. To address this, a combination strategy integrating chemotherapy and immunotherapy was employed by co-delivering epirubicin (EPI) and the immune modulator imiquimod (IMQ) using a folate-modified nanocarrier. A hydroxyethyl starch-based epirubicin prodrug modified with folic acid (FA-HES-EPI) was first synthesized to improve tumor selectivity. FA-HES-EPI/IMQ micelles were then fabricated via nanoprecipitation by encapsulating IMQ into the hydrophobic core, aiming to achieve synergistic therapeutic efficacy. Folate modification conferred tumor-targeting capability to the micelles and promoted efficient cellular uptake via folate receptor-mediated endocytosis. The acid-sensitive hydrazone bond enabled controlled release of both EPI and IMQ in the acidic tumor microenvironment, thereby enhancing their combined chemo-immunotherapeutic effects. In an orthotopic BC model, FA-HES-EPI/IMQ micelles significantly enhanced drug accumulation at the tumor site, repolarized M2-type tumor-associated macrophages (TAMs) toward the M1 phenotype, remodeled the tumor stroma, and achieved a tumor inhibition rate of 96.7%, markedly surpassing that of FA-HES-EPI micelles (86.6%) and free EPI (62.3%), with negligible systemic toxicity. This pH-responsive co-delivery system represents a promising approach to improve both efficacy and safety in bladder cancer treatment.

Sarcopenia and recurrence risk in high-risk non-muscle-invasive bladder cancer: a nonlinear modeling approach.

Intravesical hematoporphyrin photodynamic therapy combined with pirarubicin for intermediate and high-risk non-muscle-invasive bladder cancer: A multicenter, prospective single-arm cohort.

Computational analysis of the impact of urine volume on magnetic nanoparticle hyperthermia in the treatment of non-muscle-invasive bladder cancer.

Adapting patient priorities care for older adults with non-muscle-invasive bladder cancer: A qualitative inquiry.

Glycoprotein biomarkers for bladder cancer detection.

Does the urinary microbiome reflect the bladder-cancer-associated microbiome? Characterizing the microbiome in urine and cancer tissue in bladder cancer.

ASO Author Reflections: Tumor Laterality as a Key Determinant of Pelvic Lymph Node Dissection Strategy in Bladder Cancer.

Impact of pelvic lymph node dissection on oncological outcomes in patients with clinically staged non-muscle-invasive bladder cancer undergoing radical cystectomy: A systematic review.

Clinical correlates of key autophagic markers, ATG4B, LC3 and p62 in urothelial carcinoma of bladder patients.

Insulin resistance: The central node of convergence between unfolded protein response, diabetes, and cancer.